Day: March 6, 2025

Acorn’s 2024 Net Income Rises to $2.51 Per Share, Including $1.77 Per Share in Deferred Income Tax Benefit, vs. $0.05 Per Share in 2023, on 36% Revenue Increase; Announces Plan to Pursue Uplisting to Nasdaq Capital Market

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

Investor Call Today at 11am ET WILMINGTON, Del., March 06, 2025 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN), a provider of remote monitoring and control IoT solutions for backup power generators, gas pipelines, air compressors and other mission critical assets, announced results for its fourth quarter (Q4’24) and full-year periods ended December 31, 2024, which included a $4.4M non-cash benefit for deferred income taxes. Acorn also announced that it plans to pursue an uplisting to the Nasdaq Capital Market in the first half of this year. Acorn will hold an investor call today at 11am ET (details below). Summary Financial Results (1) ($ in thousands) Q4’24 Q4’23 % Change 2024 2023 % ChangeMonitoring revenue $ 1,203 $ 1,090 +10.4 % $ 4,553 $ 4,262 +6.8 %Hardware...

America’s Car-Mart Reports Third Quarter Fiscal Year 2025 Results

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

ROGERS, Ark., March 06, 2025 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the third quarter ended January 31, 2025. Third Quarter Key Highlights (FY’25 Q3 vs. FY’24 Q3, unless otherwise noted)Total revenue was $325.7 million, up 8.7% Sales volumes increased 13.2% to 13,198 units Interest income increased $3.0 million, up 5.1% Total collections increased 5.2% to $176.3 million Gross margin percentage increased 150 basis points to 35.7% Allowance for credit loss improved to 24.31%, down from 24.72% sequentially Net charge-offs as a % of average finance receivables improved to 6.1% vs. 6.8% Interest expense increased 1.1%, but was down $1.1 million sequentially Diluted earnings per share of $0.37 vs. a loss per share of $1.34 Completed...

Smart Share Global Limited Announces Third Quarter 2024 Results

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

POIs1 operated through network partner model reached 96.8% as of the end of the third quarter of 2024Cumulative registered users2 reached 430.2 million as of the end of the third quarter of 2024 SHANGHAI, March 06, 2025 (GLOBE NEWSWIRE) — Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced its unaudited financial results for the quarter ended September 30, 2024. HIGHLIGHTS FOR THE THIRD QUARTER OF 2024As of September 30, 2024, the Company’s services were available in 1,274 thousand POIs, compared with 1,267 thousand as of June 30, 2024. As of September 30, 2024, the Company’s available-for-use power banks3 were 9.5 million. As of September 30, 2024, cumulative registered users reached 430.2 million, with 13.1 million newly...

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Written by Customer Service on March 6, 2025. Posted in Public Companies.

VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3 Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, approximately a 110% increase since last earnings report Phase 2 EoE trial for VOQUEZNA nearing initiation, with first patient enrollment planned for Q2 2025 Management to host conference call today, March 6, 2025, at 8:30 a.m. ETFLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates. “VOQUEZNA’s...

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Written by Customer Service on March 6, 2025. Posted in Public Companies.

Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans’ Administration Special Emphasis Panel on Precision Oncology Trial builds on promising clinical evidence supporting a PARP inhibitor and temozolomide combination in Small Cell Lung CancerBoston (March 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating chemotherapy agent, for the treatment of recurrent Small Cell Lung Cancer (SCLC). The trial is fully funded by the U.S. Veterans Administration...

Global Uranium Corp. Signs Letter of Engagement with Big Rock Exploration to Advance Phase II Exploration at the Wyoming Group of Projects

Written by Customer Service on March 6, 2025. Posted in Public Companies.

Global Uranium Advances Exploration Strategy with Phase II Program in Wyoming CALGARY, Alberta, March 06, 2025 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the “Company”) is pleased to announce that it has signed a Letter of Engagement (“LOE”) with Big Rock Exploration LLC (“BRE”) to commence Phase II exploration activities on the Company’s Wyoming Group of Projects. The engagement with BRE represents the next step forward in refining exploration targets across the Airline, Jeep, WAC, Big Bend, and Jabs properties, located in key uranium districts within Wyoming. Under the terms of the engagement, BRE will develop an exploration framework by integrating historical data, geologic mapping, and radiometric survey results to identify high-priority drill targets. This initiative builds...

Seanergy Maritime Reports Record Full Year Profitability; Reports Fourth Quarter and Twelve Month Financial Results for the Periods Ended December 31, 2024; Declares Quarterly Cash Dividend of $0.10 Per Share

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

Highlights (in million USD, except EPS and TCE) Q4 2024 Q4 2023 12M 2024 12M 2023 YoY Growth (%)Net revenues $41.7 $39.4 $167.5 $110.2 +52%Net income $6.6 $10.8 $43.5 $2.3 Record ProfitabilityAdjusted net income1 $7.1 $11.4 $48.8 $11.7EBITDA1 $19.9 $23.3 $92.6 $51.3 +81%Adjusted EBITDA1 $20.4 $23.9 $98.4 $53.0 Fleet TCE2 $23,179 $24,920 $25,063 $17,501 +43% Earnings per share Basic $0.32 $0.55 $2.12 $0.12 +1,667%Earnings per share Diluted $0.32 $0.55 $2.11 $0.12 Adjusted earnings per share Basic1 $0.34 $0.58 $2.39 $0.63 +279Adjusted earnings per share Diluted1 $0.34 $0.58 $2.38 $0.63 Other Highlights and Developments:Record full year profitability of $43.5 million Fleet TCE outperformed the Baltic Capesize Index...

Sunrise Realty Trust, Inc. Announces Financial Results for Fourth Quarter and Year Ended 2024

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

Fourth quarter 2024 GAAP net income of $1.9 million or $0.27 per basic weighted average common share and Distributable Earnings(1) of $2.0 million or $0.30 per basic weighted average common share Year ended 2024 GAAP net income of $6.9 million or $1.01 per basic weighted average common share and Distributable Earnings(1) of $7.2 million or $1.07 per basic weighted average common share WEST PALM BEACH, Fla., March 06, 2025 (GLOBE NEWSWIRE) — Sunrise Realty Trust, Inc. (NASDAQ:SUNS) (“SUNS” or the “Company”) today announced its results for the fourth quarter and year ended December 31, 2024. SUNS reported generally accepted accounting principles (“GAAP”) net income of $1.9 million or $0.27 per basic weighted average common share and Distributable Earnings of $2.0 million or $0.30 per basic weighted average common share for the fourth...

Marex Group plc announces record fourth quarter and full year 2024 results

Written by Customer Service on March 6, 2025. Posted in Earnings Releases And Operating Results.

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) — Marex Group plc (‘Marex’ or the ‘Group’; Nasdaq: MRX) a diversified global financial services platform, providing essential liquidity, market access and infrastructure services to clients in the energy, commodities and financial markets, today reported financial results for the fourth quarter (‘Q4 2024’) and year ended 31 December 2024 (‘2024’). Ian Lowitt, Group Chief Executive Officer, stated, “I’m pleased to confirm that robust levels of client activity and positive market conditions led to another strong performance in the fourth quarter, typically a slower quarter seasonally. This delivered a full year Adjusted Profit Before Tax1 of $321.1 million, up 40% year-over-year. Our performance in 2024 demonstrates the strength and scalability of our...

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Written by Customer Service on March 6, 2025. Posted in Public Companies.

HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer. “Receiving Orphan Drug Designation for Rhenium (186Re) Obisbemeda marks a significant milestone in our efforts to develop a much-needed therapy for lung cancer patients with leptomeningeal metastases,” said Mike Rosol, Ph.D., Plus Therapeutics Chief Development Officer. “These patients currently have limited treatment options, and the growing incidence...

Day: March 6, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals